Dive into the science of precision cancer medicine at Knight School

Targeted therapy drugs have transformed the outlook for people diagnosed with one form of blood cancer, chronic myeloid leukemia. A disease with a three- to five-year life expectancy became, for...

Solving the problem of drug-resistant cancer

To discover ways to prevent or delay resistance to cancer therapies, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt. The first successful targeted...

Zeroing in on drug combos against a formidable form of leukemia

A heat map by Kurtz et al. comparing the sensitivities of leukemia cells to drug combinations. Darker red indicates drug combinations exhibiting higher efficacy than either agent alone. Targeted...

The cancer drug that “changed everything”

Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A...

How a formidable leukemia subverts blood stem cells

New findings open a path for developing desperately needed therapies for the most frequently diagnosed leukemia in adults.   Leukemia paves the way for its deadly advance by manipulating the...

This is what a ‘game changing’ cancer therapy looks like

Life expectancy in patients with chronic myeloid leukemia has soared to a level almost equal to that of the general population, according to a Swedish study quantifying the life-saving impact of...

Overcoming the impasse in acute myeloid leukemia research

Nine drug companies and six universities have now joined an unusual collaboration to break the logjam in research on acute myeloid leukemia (AML), a blood cancer lacking effective treatments....

MicroRNA as an early biomarker of leukemia

A preclinical study led by an OHSU Knight Cancer Institute physician may point the way to more effective tests for recurrence of acute myeloid leukemia. Nearly half of patients diagnosed with...